Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom

Share:
Related DXCM
Good News For Apple Watch: FDA Steps Back From App Regulation
Dexcom Registers 89.3K Shares For Sale

In a report published Friday, Jefferies & Company reiterated its Buy rating on DexCom (NASDAQ: DXCM), but lowered its price target from $18.00 to $16.50.

Jefferies noted, “DexCom released final 3Q revenues of $23.1mn after pre-announcing in early October with the G4 Platinum Sensor approval. The final 3Q numbers reflect a handful of one-time charges and adjustments; full year guidance was reiterated. The G4 and the subsequent pump combinations set the table for a good run.”

DexCom closed on Thursday at $13.07.

Latest Ratings for DXCM

DateFirmActionFromTo
Feb 2015JefferiesMaintainsBuy
Feb 2015JP MorganMaintainsOverweight
Jan 2015Sterne AgeeDowngradesBuyNeutral

View More Analyst Ratings for DXCM
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DXCM)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→